Our News
Alnylam Releases 2nd Annual Patient Access Philosophy Report
December 7, 2020
Alnylam Pharmaceuticals
When we first published the Alnylam Patient Access Philosophy in 2017, we had no way of anticipating the extraordinary developments of 2020 brought on by the global COVID-19 pandemic and how significantly they’d impact patients and their access to medicines and healthcare. As we publish our second annual readout on our progress – our 2020 Patient Access Philosophy Report, the way we think about and approach patient access seems more urgent than ever.
At Alnylam, we have a shared philosophy when it comes to patient access: our innovative therapies must get to those who may benefit from them. This philosophy of putting the patient first isn’t just a belief common among our leadership and employees, it’s a statement of intent and a specific set of actions that we’ve undertaken as a company.
Our Patient Access Philosophy recognizes that Alnylam has a critical role to play beyond our science and the development of drugs, which is that a biopharmaceutical company’s actions to help ensure access must be bigger than just those related to insurance coverage and reimbursement.
Beyond discovery and development of our medicines, our job is to listen to patients, payers and providers, and then to respond thoughtfully, collaboratively and transparently with actions and programs to help as many people as possible who need access to these treatments and associated care. Especially in times like these, access is about flexibility in points of care as much as it is about addressing financial burdens and coverage. - John Maraganore, Ph.D, Alnylam CEO
We know that to make our commitment to access more than mere words, we must continually track and assess our progress and regularly report our findings, and so we have defined a series of quantifiable and transparent metrics that allow us to measure our progress against three key guiding beliefs: patients come first, innovation is key in everything we do and accountability is a must. These metrics form the basis of our Patient Access Philosophy Report.
The report highlights Alnylam’s achievements in the U.S. as well as our expansion into other markets like CEMEA (Central Europe, Middle East and Africa). It also addresses the progress we have made in supporting access to our RNAi therapeutics and how Alnylam has addressed needs related to site of care, COVID-19, evolving local policies and advocacy, and various other matters.
Highlights from the 2020 Patient Access Philosophy Report:
Helping patients from clinical development through commercialization...
- 11 programs providing access to investigational medicines currently in clinical development
- >540 U.S. patients enrolled in Alnylam Assist for ONPATTRO or GIVLAARI
- Home administration:
- 20% average U.S. patients on ONPATTRO and GIVLAARI
- 7 EU countries offer homecare for ONPATTRO
Improving diagnosis and providing education...
- ~30,000 people genotyped through Alnylam Act across three programs (TTR, AHP, PH1)
- Patient Empowerment Group for Access and Sustainability (PEGASUS) – an educational effort through advocacy support program is now available in 14 countries in Europe
Breaking down barriers to expedite access to treatment...
- Signed two new pledges in the U.S. and Europe, helping lead the industry closer to a model that prioritizes access
- Realized greater than 90% coverage for ONPATTRO and GIVLAARI across U.S. commercial and government insurers, including Medicare and Medicaid
- Achieved reimbursed access to ONPATTRO and GIVLAARI an average of 11 months faster than other orphan drugs in major European countries
Delivering value to patients and payers...
- Nearly 30 value-based agreements (VBAs) with U.S. payers, two thirds of them for ONPATTRO and the remainder for GIVLAARI
- >98% for ONPATTRO and >90% for GIVLAARI: U.S. lives with confirmed access across commercial, Medicare, Medicaid and other government payer categories
- >50 CEMEA markets have access to ONPATTRO via direct contracts or distributor agreements
We hope that you will take the time to read the 2020 Patient Access Philosophy Report and learn how we are doing our part to improve access worldwide.
